Neurological Complications Of Systemic Cancer Research Articles

Adaptive Staged-Dose Gamma Knife Radiosurgery for the Treatment of Large Brain Metastases: Report of 40 Consecutive Cases and Analysis of Literature.

Brain metastases are the most common brain tumors, being one of the most frequent neurological complications of systemic cancer and an important cause of morbidity and mortality. Stereotactic radiosurgery is efficacious and safe in the treatment of brain metastases, with good local control rates and low adverse effects rate. Large brain metastases present some issues in balancing local control and treatment-related toxicity. Demonstrating adaptive staged-dose Gamma Knife radiosurgery (ASD-GKRS) being a safe and effective treatment for large brain metastases. We retrospectively analyzed our series of patients treated with two-stage Gamma Knife radiosurgery for large brain metastases in [BLINDED], between February 2018 and May 2020. Forty patients with large brain metastases underwent adaptive staged-dose Gamma Knife radiosurgery, with median prescription dose of 12 Gy and a median interval between stages of 30 days. At three-month follow-up, the survival rate was 75.0% with a local control rate of 100%. At six-month follow-up, the survival rate was 75.0% with a local control rate of 96.7%. The mean volume reduction was 21.81 cm3 (16.76-26.86; 95% CI). The difference between baseline volume and six-month follow-up volume was statistically significant. Adaptive staged-dose Gamma Knife radiosurgery is a safe, non-invasive and effective treatment for brain metastases, with a low rate of side effects. Large prospective trials are needed to strengthen data obtained about the effectiveness and safety of this technique in managing large brain metastases.

Stereotactic radiosurgery for single or oligometastatic brain lesions: A single institutional experience

Aim: Intracranial metastases are the most common neurologic complications of systemic cancer. Stereotactic radiosurgery (SRS) is a proven modality for treating single or oligometastatic brain lesions. In this retrospective study, we have analyzed patients data treated in our hospital with SRS. Materials and Methods: The analysis included 52 patient's data treated between August 2010 and January 2018. These include the patients in the complete remission of the primary disease and have recurred in the brain with one to four metastases after a significant disease-free interval. Patient's case sheets and treatment planning system data were analyzed to collect the data for this study. Results: Median follow-up was 10 months (range, 1–37 months). There were twenty cases of Ca (cancer) lung, 13 cases of Ca breast, 5 cases of Ca rectum, 4 cases of Ca endometrium, 2 case of Ca esophagus, and 1 case each of alveolar rhabdomyosarcoma of right parotid, Ca ovary, Ca vaginal vault, Ca lacrimal gland, Ca colon, Ca urinary bladder, and Ca prostate. These patients who had a recurrent disease in the brain were treated with doses ranging from 15 to 20 Gy in single fraction, 24 Gy in 3 fractions, 27 Gy in 3 fractions, or 30 Gy in 5 fractions. Median progression-free survival was 9 months, and median overall survival (OS) was 12 months in these patients. Conclusion: Frameless SRS is an effective treatment of delivering high-dose radiation to patients who develop one to four brain metastasis with comparable median progression free and OS to the previously reported data.

Neurological Complications of Systemic Cancer and Antineoplastic TherapyNeurological Complications of Systemic Cancer and Antineoplastic Therapy edited byNewtonHerbert B.MalkinMark G.,590 pp.,Informa Healthcare, 2010, $199.95

Neurological Complications of Systemic Cancer and Antineoplastic Therapy edited by Herbert B. Newton, Mark G. Malkin, 590 pp., Informa Healthcare, 2010, $199.95 Nothing offers more diagnostic challenges or therapeutic wrinkles for the consulting neurologist than the oncology unit. Patients have complex, multisystem disease. Therapies have narrow therapeutic windows and side effects that can range from the fulminant and devastating to the insidious and subtle. …

Surgical Therapies in Brain Metastasis

Brain metastases are the most common intracranial tumors in adults and source of the most common neurological complications of systemic cancer. The treatment approach to brain metastases differs essentially from treatment of systemic metastases due to the unique anatomical and physiological characteristics of the brain. Surgery and radiosurgery are important components in the complex treatment of brain metastases and can prolong survival and improve the quality of life (QOL). Aggressive intervention may be indicated for selected patients with well-controlled systemic cancer and good performance status in whom central nervous system (CNS) disease poses the greatest threat to functionality and survival. In this review the respective roles of surgery and radiosurgery, patient selection, general prognostic factors and tailoring of optimal surgical management strategies for cerebral metastases are discussed.

Neurological Complications of Systemic Cancer

Neurological complications of cancer are an extensive group of disorders that can be devastating for the patient. These complications are caused by invasion of the nervous system by tumor cells or by indirect mechanisms, in which case the pathogenesis often differs from that in the noncancer population. Neuroimaging and other diagnostic techniques can facilitate the diagnosis of metastatic complications but are less definitive for the latter group of disorders, which often require neuro-oncological assessment.

Complicaciones neurológicas de las enfermedades extraneurológicas: del protagonismo a la comorbilidad

The development of scientific advances, constantly opening new frontiers of knowledge, leads to increasing complexity and specialization.The conflict between the never ending medical specialization and the opposite tendency, which is based mostly on economic grounds, prevents the acquisition of new knowledge across different disorders and diseases. Considering the brain as a complex adaptative system, it follows that in order to understand its pathogenic mechanisms and to design new therapies, the study of the interrelation of all parts concerned must be undertaken. Such approach requires the use of increasingly complex degrees of knowledge, covering different fields and disciplines. A first step might be the study of neurological complications of non neurological disorders. The former should leave its principal status in order to be studied as a consequence of the latter by disconcerted neurologists. The neurological complications of systemic cancer, congenital cardiopathy and autoinmune diseases are good examples of the need for a multidisciplinary approach to achieve a satisfactory capacity of diagnosis and treatment.

Office Practice of Neurology

Part 1 Principles of ambulatory neurology and the approach to clinical problems: principles of diagnosis - the general approach to neurologic diagnosis principles of diagnosis - common presenting symptoms and findings principles of diagnosis - special tests principles of treatment. Part 2: general aspects of cerebrovascular disease common pathogenesis of stroke less common causes of stroke management of cerebrovascular disease. Part 3 Infectious diseases: diseases of the spinal cord motor neuron diseases diseases of peripheral nerve diseases of neuromuscular transmission diseases of muscle. Part 4: Parkinson's Disease and Parkinson-like syndromes non-Parkinsonian movement disorders. Part 5: behavioural neurology epilepsy disorders of sleep psychiatric issues in neurologic practice. Part 6: brain tumours - specific tumour types spinal cord tumours neurologic complications of systemic cancer. Part 7: cardiology and cardiac surgery pulmonary disorders nephrology and urology gastronenterology and hepatology haematology endocrinology and metabolism toxins and drug effects organ transplantation rheumatology. Part 8: general aspects of headache headache syndromes and their treatment special headache problems general aspects of pain generalized pain syndromes regional pain syndromes.

Neurologic Involvement of Systemic Cancer

Neurologic complications of systemic cancer often represent neurologic emergencies. Nonneoplastic neurologic complications are common in cancer patients. Even the treatment of cancer often causes neurotoxicities. Nurses working in critical areas frequently care for these patients. Early diagnosis and treatment improves the patient's outcome in most cases. It is imperative that nurses recognize the signs and symptoms of neurologic complications of systemic cancer.

Neurologic complications of systemic cancer

Neurologic complications of systemic cancer are common. Metastatic complications include intracranial metastasis, spinal metastasis, leptomeningeal metastasis, and metastasis to peripheral nerves. Treatment is often effective in preventing further neurologic disability and pain. Early diagnosis is important. Nonmetastatic complications of systemic cancer include a wide variety of neurologic illnesses that can also occur in the noncancer population. The most common is toxic metabolic encephalopathy. Other nonmetastatic complications include cerebrovascular complications, complications of treatment, immunocompromised infections, and paraneoplastic syndromes.

The Neuro-Oncology Register.

In this report we describe the establishment of a Neuro-Oncology Register (NOR) at the University Hospital of Maastricht, The Netherlands. The register includes data on numbers and types of primary central nervous system (CNS) tumours and neurological complications of systemic cancer. One of the objectives of the register is to determine the incidence rate of neuro-oncological complications in systemic tumours and the incidence and prevalence rates of primary CNS tumours in a well-defined population. The catchment area of the NOR was defined with the help of the Dutch Regional Cancer Register. It involves 140,819 inhabitants and will be considered as our catchment population. At present, 1,168 cases have been recorded since the NOR became operational. All neuro-oncological reports in 1988 were chosen for further analysis (n = 276). We diagnosed 79 metastatic complications from systemic cancer. Metastasis of the brain is the most frequent metastatic complication in our population, followed by epidural metastasis. As in other series, the lung and breast are the most frequently encountered tumour sites. The NOR is a clinically based register which, in co-operation with the Dutch Regional Cancer Register, will generate important epidemiological data on CNS complications.

Neurologic Complications of Systemic Cancer

Patients with cancer commonly suffer neurologic disabilities. These neurologic disorders can be either metastatic to the brain, spinal cord, leptomeninges, or peripheral nerves or nonmetastatic including infections, vascular problems, metabolic abnormalities, side effects of therapy, or paraneoplastic syndromes. Careful diagnostic evaluation of patients with cancer and neurologic symptoms often indicates effective therapy.

Neurologic Complications of Systemic Cancer

Neurologic complications of systemic cancer may result from metastatic spread of tumor to the central nervous system, from paraneoplastic effects of peripheral tumor, or from side effects of anticancer therapy. This article outlines currently available data on clinical presentations of these complications and diagnostic modalities for their recognition, data which may help the clinician ameliorate the often devastating sequelae of these neurologic complications.

Neurological Complications of Systemic Cancer

Neurological Complications of Systemic Cancer

Neurologic complications of systemic cancer

Brain metastasis (BM) from breast cancer is increasingly encountered clinically because of the continuing success in the oncological control of the primary disease. Data-driven reports on the surgical treatment of BM from breast cancer are sparse in sub-Saharan Africa.This is a prospective cohort study of the outcome of surgical excision of BM from breast cancer in an academic surgical practice in Ibadan, Nigeria.A total of 12 consecutive cerebral metastasectomies, all in females with primary breast cancer, were recorded over the study period. The median age (range) at breast cancer diagnosis was 41 (27–72) years, and the time interval from primary disease to BM was 19 (12–29) months. The BM was the first site of systemic disease progression in all, and was heralded by headache, seizures, and hemiparesis in more than two-thirds of the patients. The brain lesions were multiple in a quarter: >4 cm large in 42% and were located supratentorial in >80%. They all achieved good recovery and in-hospital outcome after surgical lesionectomy—infra- and supratentorial craniotomies—but only two-thirds could access postsurgical adjuvant whole brain radiation therapy. Median survival after cerebral metastasectomy was 18 (11–55) months, and more than a quarter were alive for ≥3years. These survival statistics were significantly better than those of a contemporary cohort of our patients with breast cancer who also had BMs that were not surgically treated for various clinical and logistic limitations.Surgical resection is feasible for BM from breast cancer even in low-resource clinical practice. It has a salutary effect on the patients' quality of life.

Neurological Complications of Systemic Cancer

Neurological Complications of Systemic Cancer